返回 
加入收藏
胎盘多肽用于非小细胞肺癌高龄化疗患者的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 胎盘多肽用于非小细胞肺癌高龄化疗患者的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察胎盘多肽用于非小细胞肺癌（NSCLC）高龄化疗患者的临床疗效及毒副反应。方法：将110例NSCLC高龄化疗患者按随机数字表法分为观察组与对照组，各55例。对照组患者给予培美曲塞+顺铂方案化疗，3周为一周期，化疗4个周期；观察组患者在对照组基础上加用胎盘多肽注射液8 ml加入0.9％氯化钠注射液200 ml中，ivgtt，bid，每个化疗周期连续治疗10 d。观察两组患者临床疗效及治疗前后外周血T淋巴细胞亚群与NK细胞活性水平，比较治疗前后卡氏（KPS）评分、无进展生存期（PFS）、总生存期（OS）及白细胞计数（WBC）、血红蛋白（Hb）、血小板计数（PLT）、乏力症状评分以评价毒副反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）；治疗后，观察组患者外周血T淋巴细胞亚群CD3+、CD4+、CD4+/CD8+与NK细胞活性均显著高于对照组，差异有统计学意义（P＜0.05）；治疗后观察组患者KPS评分明显高于对照组，差异有统计学意义（P＜0.05）；观察组患者PFS、OS显著长于对照组，差异有统计学意义（P＜0.05）；治疗后，观察组患者WBC计数、Hb水平和PLT计数均显著高于对照组，乏力症状评分显著低于对照组，差异均有统计学意义（P＜0.05）。结论：胎盘多肽能显著提高NSCLC高龄化疗患者的临床疗效，改善机体免疫功能，减轻毒副反应。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and ADR of placenta polypeptide for advanced aged chemotherapy patients with non-small cell lung cancer （NSCLC）. METHODS： 110 advanced age chemotherapy patients with NSCLC were randomly divided into observation group and control group， with 55 cases in each group. Control group was given chemotherapy regimen of pemetrexed+cisplatin， 3 weeks as a chemotherapy course， for 4 courses； observation group was additionally given Placenta polypeptide injection 8 ml+0.9％ Sodium chloride solution 200 ml， ivgtt， bid， 10 days as a chemotherapy course， on the basis of control group. Clinical efficacy was observed in 2 groups， T lymphocyte subsets and NK cell activity were also observed before and after treatment. KPS， WBC， Hb， PLT and fatigue symptom score were compared before and after treatment， and toxic reaction was evaluated. RESULTS： Total effective rate of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. After treatment， T lymphocyte subsets CD3+， CD4+ and CD4+/CD8+ and NK cell activity of observation group were significantly higher than those of control group， with statistical significance （P＜0.05）； while KPS of observation group was significantly higher than that of control group after treatment， with statistical significance （P＜0.05）. Observation group of patients with OS， PFS was significantly longer than that of control group， the difference was statistically significant （P＜0.05）.After treatment， WBC， Hb and PLT count of observation group were significantly higher than those of control group， symptom scores were significantly lower than those in the control group with statistical significance （P＜0.05）. CONCLUSIONS： The placental peptide can significantly improve clinical efficacy， immune function and reduce toxic reaction in advanced age chemotherapy patients with NSCLC. |
| 期刊： | 2016年第27卷第14期 |
| 作者： | 马东阳，崔庆丽，胡彦辉 |
| AUTHORS： | MA Dongyang，CUI Qingli，HU Yanhui |
| 关键字： | 非小细胞肺癌；化疗；胎盘多肽；高龄患者 |
| KEYWORDS： | Non-small cell lung cancer； Chemotherapy； Placenta polypeptide； Advanced age patient |
| 阅读数： | 498 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
